β-Glucuronidase Is an Optimal Normalization Control Gene for Molecular Monitoring of Chronic Myelogenous Leukemia

This publication has 20 references indexed in Scilit:

• Molecular Monitoring of Chronic Myelogenous Leukemia
  The Journal of Molecular Diagnostics, 2006
• Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
  Cancer, 2005
• Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse
  Leukemia, 2005
• Clinical Pharmacokinetics of Imatinib
  Clinical Pharmacokinetics, 2005
• Loss of Response to Imatinib: Mechanisms and Management
  Hematology-American Society Hematology Education Program, 2005
• Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
  Blood, 2004
• Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C δ
  Genes & Development, 2004
• Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease – a study within the Europe Against Cancer Program
  Leukemia, 2004
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
  Leukemia, 2003
• Quantitative real‐time reverse‐transcription polymerase chain reaction for diagnosis of BCR‐ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation
  European Journal of Haematology, 2003